tetano
Editor, Senior Moderator
J Pharmacol Pharmacother. 2011 Apr;2(2):100-3.
Adverse drug reaction profile of oseltamivir in children.
Dalvi PS, Singh A, Trivedi HR, Mistry SD, Vyas BR.
Source
Department of Pharmacology, MP Shah Medical College, Jamnagar 361 008, Gujarat, India.
Abstract
AIM:
To monitor and evaluate the pattern of ADRs to oseltamivir in pediatric population suffering from H1N1 influenza at a tertiary care hospital.
MATERIALS AND METHODS:
Children offered oseltamivir for treatment and chemoprophylaxis were monitored for adverse events by direct questioning for symptoms and clinical examination on day 5 and day 10. Assessment of neurological events was done by asking the parents or guardians regarding development of specific symptoms. Adverse events obtained were analyzed for severity, causality and age-group wise.
RESULTS:
Out of 191 children (median age, 3 years), 69 (36.1%) developed ADRs. Most common symptoms were vomiting (16.2%) followed by diarrhea (12.0%), ear disorders (8.9%), and insomnia (6.8%). The incidence of neuropsychiatric symptoms was 12.6% which were mild-to-moderate on severity scale. There was no significant difference in the incidence of adverse events between children less than 1 year and other age groups.
CONCLUSION:
Oseltamivir is well tolerated in Indian children with suspected or confirmed H1N1 influenza. Our study also indicates safety of oseltamivir in infants.
PMID:
21772769
[PubMed - in process]
Free PMC Article
http://www.ncbi.nlm.nih.gov/pubmed/21772769
Adverse drug reaction profile of oseltamivir in children.
Dalvi PS, Singh A, Trivedi HR, Mistry SD, Vyas BR.
Source
Department of Pharmacology, MP Shah Medical College, Jamnagar 361 008, Gujarat, India.
Abstract
AIM:
To monitor and evaluate the pattern of ADRs to oseltamivir in pediatric population suffering from H1N1 influenza at a tertiary care hospital.
MATERIALS AND METHODS:
Children offered oseltamivir for treatment and chemoprophylaxis were monitored for adverse events by direct questioning for symptoms and clinical examination on day 5 and day 10. Assessment of neurological events was done by asking the parents or guardians regarding development of specific symptoms. Adverse events obtained were analyzed for severity, causality and age-group wise.
RESULTS:
Out of 191 children (median age, 3 years), 69 (36.1%) developed ADRs. Most common symptoms were vomiting (16.2%) followed by diarrhea (12.0%), ear disorders (8.9%), and insomnia (6.8%). The incidence of neuropsychiatric symptoms was 12.6% which were mild-to-moderate on severity scale. There was no significant difference in the incidence of adverse events between children less than 1 year and other age groups.
CONCLUSION:
Oseltamivir is well tolerated in Indian children with suspected or confirmed H1N1 influenza. Our study also indicates safety of oseltamivir in infants.
PMID:
21772769
[PubMed - in process]
Free PMC Article
http://www.ncbi.nlm.nih.gov/pubmed/21772769